We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) of non-WT isolates for itraconazole and posaconazole, respectively. Amphotericin B MICs of ≥2 μg/ml and micafungin minimum effective concentrations (MECs) of ≥16 μg/ml were recorded for two and one isolates, respectively. Copyright © 2012, American Society for Microbiology. All Rights Reserved.
CITATION STYLE
Tashiro, M., Izumikawa, K., Minematsu, A., Hirano, K., Iwanaga, N., Ide, S., … Kohno, S. (2012). Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrobial Agents and Chemotherapy, 56(1), 584–587. https://doi.org/10.1128/AAC.05394-11
Mendeley helps you to discover research relevant for your work.